ArticleScientific reports2025
A Finnish nationwide population-based study on the survival of patients with peripheral T-cell lymphoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peripheral T-cell lymphomas (PTCLs) represent a heterogeneous group of rare malignancies with poor survival; however, population-based long-term survival data remain limited. We conducted a nationwide study to estimate overall survival (OS) and relative survival (RS) among 915 patients diagnosed with PTCLs from 2002 - 2018 (57% males, median age 67 years) using the Finnish Cancer Registry. The most common subtypes included PTCL not otherwise specified (PTCL NOS; 37%), angioimmunoblastic T-cell lymphoma (AITL; 27%), and ALK-anaplastic large cell lymphoma (ALK-ALCL; 12%). Age > 60 years at diagnosis, advanced stage, and male sex were associated with poorer OS. Five-year OS and RS were better in patients with ALK + ALCL compared with PTCL NOS (5-year OS: 85% vs 30%). Patients with ALK- ALCL had a favorable 5-year OS compared to PTCL NOS (46% vs 30%), while those with enteropathy-associated T-cell lymphoma (EATL) demonstrated worse OS (15%). There was no improvement in RS from 2002 - 2012 to 2013 - 2018. OS was better in patients (excluding ALK + ALCL) receiving high-dose chemotherapy (HDCT) compared to those for whom HDCT was not planned (HR 0.61; 95% CI 0.47 - 0.80). We conclude that RS did not improve during the study period; however, consolidation with HDCT for eligible patients resulted in favorable survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.